| Regulatory Rapporteur May 2022 | MEMBERS |
| Practical insights into the recent EU MDR framework | MEMBERS |
| Gene therapy products: regulatory expectations and challenges for industry | MEMBERS |
| Procedure withdrawals within Europe: past trends, impact and communication recommendations | MEMBERS |
| CMC considerations for US biosimilars development | MEMBERS |
| Regulatory Framework for Platform Technologies | MEMBERS |
| A regulatory view on the change management process for medicinal products | MEMBERS |
| Amgen's experience of global expedited regulatory pathways in the development of sotorasib | MEMBERS |